Good Sport
1 week ago
Loc,
Any guess as to when that 11,105,808 B patent will expire? I didn't quite understand the prior patents that made up this and then the * mark stating it was subject to early "terminal" termination whatever that means. It also has a little over a year of additional extention to it from uspto.
Also, do you think NeoGenomics is still in our mix again as possible partners for this? I see their stock price is trading at a little under $15 currently.
RELATED APPLICATIONS
This is a continuation of application Ser. No. 14/754,434, filed Jun. 29, 2015, issued as U.S. Pat. No. 9,952,221, which is a continuation of application Ser. No. 12/349,437, filed Jan. 6, 2009, now abandoned, which is a continuation-in-part of application Ser. No. 12/327,823, filed Dec. 4, 2008, now abandoned, which is a continuation-in-part of application Ser. No. 12/025,724, filed Feb. 4, 2008, now abandoned, which claims the priority of Provisional Application No. 60/888,070, filed Feb. 2, 2007, and is a continuation-in-part of application Ser. No. 11/274,931, filed Nov. 14, 2005, now abandoned, which claims the priority of each of Provisional Applications No. 60/627,626, filed Nov. 12, 2004, and No. 60/651,340, filed Feb. 9, 2005.
Patent History
Patent number: 11105808
Type: Grant
Filed: Apr 12, 2018
Date of Patent: Aug 31, 2021
Patent Publication Number: 20180321245
Assignee: HEALTH DISCOVERY CORPORATION (Atlanta, GA)
Inventor: Isabelle Guyon (Berkeley, CA)
Primary Examiner: Peter J Reddig
Application Number: 15/952,186
chazzy1
2 weeks ago
LocWolf, actually, my point was that, if there is anyone capable of making something happen, it would be Alan. But I tend to agree that, at this late stage of the game, and if we do not see an 8k soon, the odds for an HDC resurgence diminish with each passing day. However, given Alan's resorcefulness, connections and expertise in the field, I am not ready to write this off. I have waited this long. I might as well wait it out to the grand finale. After all, what is there to gain by selling now? A few cents? My shares won't be worth any less if I wait and HDC eventually goes belly up. But they could be worth a lot more if Alan is successful. Incidently, Colleen and her extended network of family, friends and associates have placed all of their eggs (hopes) in Alan's basket. And who knows? He may come through yet.
chazzy1
2 weeks ago
Buylow2, I wish I had a positive update for you. However, Zenos Arrow is correct. Unless HDC files a new 8k soon, it would indicate that Alan has not met his 6 month performance metric. This doesn't mean that he won't be successful ultimately, but by not meeting this milestone metric, it does mean that he stands to forfeit a bonus of 500,000 extra shares.
I remain hopeful that, if anyone can, Alan will be able to make something happen for HDC.
Good Sport
3 weeks ago
This article I kept (below) was from many years ago but states we had partnered with Pfizer...
Health Discovery Corp Hires the Dilenschneider Group
Health Discovery Corporation hires The Dilenschneider Group, a New York City IR/PR firm
SAVANNAH, Ga.- Health Discovery Corporation (OTCBB: HDVY), is pleased to announce that it has retained The Dilenschneider Group, headquartered in New York City, to manage the Company’s investor and media relations work. With offices in New York, Washington, DC and Chicago, the Dilenschneider Group provides its clients with some of the finest and most seasoned communications professionals in the world.
“We are delighted to have The Dilenschneider Group on-board to lead our newly implemented investor and media relations effort at a pivotal time in the company’s development,” said Dr. Stephen Barnhill, Chairman and CEO of Health Discovery Corporation. “The Dilenschneider Group is a highly respected corporate communications firm and we welcome their expertise to effectively communicate the Company’s exciting corporate achievements,” said Dr. Barnhill.
“We are pleased to be representing Dr. Barnhill and the Company,” said Robert Dilenschneider, Chairman of The Dilenschneider Group. “They are at the forefront in the development of an entirely new and revolutionary approach to diagnostic and personalized medicine, and we welcome this opportunity to communicate the Company’s successes,” Mr. Dilenschneider said.
HDC recently entered into royalty-bearing licenses for its new urine-based prostate cancer test to Quest Diagnostics Incorporated (NYSE: DGX ) and Abbott Laboratories (NYSE: ABT) for development and commercialization. HDC also entered into royalty-bearing licenses for its tissue biopsy-based prostate cancer test to Abbott Laboratories (NYSE: ABT) and Clarient Inc. (Nasdaq: CLRT) for development and commercialization. HDC has also partnered with Pfizer Inc. (NYSE: PFE) for use of HDC’s SVM and SVM-RFE pattern recognition technology.
A scientific paper on the association of these four genes with prostate cancer was recently published in the peer-reviewed journal, UroToday International, in its August 2009 issue. The combined results of the double-blind clinical validation studies demonstrated that the new gene-based molecular diagnostic test for prostate cancer achieved a Sensitivity of 90% for correctly identifying the presence of Grade 3 or higher prostate cancer cells, and a Specificity of 97% for correctly identifying non-cancer cells (normal and BPH), representing an overall test accuracy of 93%.
HDC’s new prostate cancer tests are based on a unique and patent protected combination of four genes that have been shown to accurately identify the presence of Grade 3 or higher prostate cancer cells in prostate tissue and urine. The association of these four genes with prostate cancer was discovered by Health Discovery Corporation using their patented SVM and SVM-RFE pattern recognition technology.
About Health Discovery Corporation
Health Discovery Corporation is a molecular diagnostics company that uses advanced mathematical techniques to analyze large amounts of data to uncover patterns that might otherwise be undetectable. It operates primarily in the emerging field of personalized medicine where such tools are critical to scientific discovery. Its primary business consists of licensing its intellectual property and developing its own product line of biomarker-based diagnostic tests that include human genes and genetic variations, as well as gene, protein, and metabolic expression differences and image analysis in digital pathology and radiology. For more information, see www.healthdiscovercorp.com.
About The Dilenschneider Group
The Dilenschneider Group is a corporate strategic consulting and investor and public relations firm headquartered in New York City and has offices in Chicago and Washington, DC. For more information, see www.dilenschneider.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, the accuracy of which is necessarily subject to risks and uncertainties, including, without limitation, statements regarding future performance, opportunities and investments, and anticipated results in general. From time to time the Company may make other forward-looking statements relating to other matters, including without limitation, commercialization plans and strategic partnerships. Actual results may differ materially due to a variety of factors, including, among other things, the acceptance of our approach to applying mathematics computer science and physics into the disciplines of biology, organic chemistry and medicine and our products and technologies associated with those approaches, the ability to develop or commercialize new drugs, therapies or other products based on our approaches, and other factors set forth from time to time in the Company’s Securities and Exchange Commission filings.
All forward-looking statements and cautionary statements included in this document are made as of the date hereof based on information available to the Company as of the date hereof, and the Company assumes no obligation to update any forward-looking statement or cautionary statement.
Contact
For Health Discovery Corporation
Matthew Swetonic, Media Relations, 212-922-0900
mswetonic@dgi-nyc.com
or
Tom Gallagher, Investor Relations, 212-922-0900
tgallagher@dgi-nyc.com
Good Sport
3 weeks ago
Might we be part of this in some small way?
IQVIA, Illumina, Mayo Clinic and Arc Institute Harness NVIDIA AI and Accelerated Computing to Transform $10 Trillion Healthcare and Life Sciences Industry
NVIDIA Partners With Industry Leaders to Advance Genomics, Drug Discovery and Healthcare
IQVIA, Illumina, Mayo Clinic and Arc Institute Harness NVIDIA AI and Accelerated Computing to Transform $10 Trillion Healthcare and Life Sciences Industry
January 13, 2025
NVIDIA Partners With Industry Leaders to Advance Genomics, Drug Discovery and Healthcare
J.P. Morgan Healthcare Conference—NVIDIA today announced new partnerships to transform the $10 trillion healthcare and life sciences industry by accelerating drug discovery, enhancing genomic research and pioneering advanced healthcare services with agentic and generative AI.
The convergence of AI, accelerated computing and biological data is turning healthcare into the largest technology industry. Healthcare leaders IQVIA, Illumina and Mayo Clinic, as well as Arc Institute, are using the latest NVIDIA technologies to develop solutions that will help advance human health.
These solutions include AI agents that can speed clinical trials by reducing administrative burden, AI models that learn from biology instruments to advance drug discovery and digital pathology, and physical AI robots for surgery, patient monitoring and operations. AI agents, AI instruments and AI robots will help address the $3 trillion of operations dedicated to supporting industry growth and create an AI factory opportunity in the hundreds of billions of dollars.
https://nvidianews.nvidia.com/news/nvidia-partners-with-industry-leaders-to-advance-genomics-drug-discovery-and-healthcare
chazzy1
1 month ago
LocWolf, this is an excellent find! Thank you! This method of screening, predicting and monitoring prostate cancer, involves patents by Guyon (2018) and Albitar (2014) which were assigned to HDC. Based upon these issue dates, these patents should have a lot of life remaining, be highly marketable and be of great interest to our CEO, Dr. Alan Hauser.
Thanks again LocWolf and Happy New Year!